Evidence map›Paper›PMID 27190245›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2016

Programmable biomaterials for dynamic and responsive drug delivery.

Anna Stejskalová, Mehrdad T Kiani, Benjamin D Almquist

Abstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anna StejskalováDepartment of Bioengineering, Imperial College London, London SW7 2AZ, UK.
Mehrdad T KianiDepartment of Bioengineering, Imperial College London, London SW7 2AZ, UK.
Benjamin D AlmquistDepartment of Bioengineering, Imperial College London, London SW7 2AZ, UK b.almquist@imperial.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomaterials are continually being designed that enable new methods for interacting dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug delivery to regenerative medicine. In this review, we explore some of the recent advances being made in regards to programming biomaterials for improved drug delivery, with a focus on cancer and infection. We begin by explaining several of the underlying concepts that are being used to design this new wave of drug delivery vehicles, followed by examining recent materials systems that are able to coordinate the temporal delivery of multiple therapeutics, dynamically respond to changing tissue environments, and reprogram their bioactivity over time.

Indexed as

AnimalsAnti-Infective AgentsAntineoplastic AgentsBiocompatible MaterialsCommunicable DiseasesDrug Delivery SystemsDrug DiscoveryHumansNeoplasmsAnti-Infective AgentsAntineoplastic AgentsBiocompatible MaterialsbacteriabiomaterialsBionanosciencecancerdrug deliverynanoparticles

Identifiers

PMID27190245
PMCPMC4950367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.